STAT News

STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.

By STAT News

1 min read
STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights